Tempus recently entered into a new deal with Precision HealthAL and CancerLinQ to help structure the huge amounts of data that CancerLinQ has currently. This technology company, Tempus, puts their focus on personalized cancer treatment by using big data to get the job done. The CancerLinQ database has been in the development stage since the establishment of CancerLinQ LLC, and it holds reports that consist of at least one million records of various patients. The CancerLinQ LLC is a non-profit entity and subsidiary of ASCO, which Dr. Clifford Hudis has mentioned is a practical arrangement similar to both Precision HealthAl and Tempus, giving them the opportunity to analyze the information in the database as a faster pace and more effective than an in-house operation.
Eric Lefkofsky, the CEO of Tempus, has given a brief overview of a certain deal that CancerLinQ was formed by ASCO to amass larger parts of patient data directly from providers. CancerLinQ was successful when gathering this data, but now the question sits wondering what should be done with the records gathered. With this challenge in mind, CancerLinQ began to seek assistance from various organizations to both analyze and structure the data. This is where Tempus and Precision HealthAL both come into play. There are major benefits coming from the structure of a larger database like CancerLinQ’s, according to Lefkosfky’s words. It could even aid biotech companies in development and drug research by using the data to help create clinical trials that are more effective. This is how Tempus intends to deliver value to the world.
Both Precision HealthAl and Tempus were chosen once CancerLinQ had concluded more commercialized data for more effective analyzation. Lefkosky notes how both companies will work together because they are complementing of one another. The CEO of Precision HealthAl notes that they will use their platform to deliver larger data amounts, while Tempus intends to focus on building their data by combining both molecular and clinical data. Tempus believes that both sets of data are important to creating personalized cancer care for patients.
Tempus was founded in 2015 by Eric Lefkoskfy. Though he never intended to enter the industry of healthcare, he found motivation in the diagnosis of cancer in someone very close to him. His experience was his motivation to create better technology and data sets within clinical practice since there seemed to be a lack of it everywhere.
As a career entrepreneur, Eric Lefkofsky has spent much of his professional life working in various industries through the power of data. He has used his experience to create various other companies like Uptake, Innerworkings, and Echo Global Logistics, and he helps co-found Groupon, a global company. His largest venture to date is the creation of Tempus, in which he hopes to help change the way cancer treatment is done on a daily basis. His own personal, life experience has given him that push to keep reaching for his dreams as well.
Lefkofsky earned both of his degrees, undergraduate and graduate, from the University of Michigan, located in the state where he was born and raised. He moved to Chicago after graduating, where he has become a huge part of his community both in the business and personal world for various reasons. Through his Lefkofsky Family Foundation and the help of his loving wife, he has helped various arts companies like the Art Institute, Museum of Science and Industry, and even Steppenwolf Theater Company, which are passions of his. Eric Lefkofsky is an extremely accomplished man, and he continues to work toward his goal of helping change the shape of cancer treatment for good.